Latest Regulatory Filings News

Activeport Group Ltd has revised the timetable for its pro-rata bonus issue of unquoted options, outlining key dates and eligible shareholders across multiple countries.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

BHP Group has officially ended talks to combine with Anglo American, choosing instead to focus on its own growth strategy. The mining giant acknowledges the strategic benefits of a merger but remains confident in its independent path forward.

Embark Early Education has revised the timeline for its conditional takeover bid of Mayfield Childcare, delaying key regulatory filings into early 2026.

5E Advanced Materials reports progress on its California boron project with a new feasibility study and equity raises, while highlighting ongoing funding uncertainties.

The Supreme Court of Western Australia has approved the share and option schemes for Capricorn Metals’ acquisition of Warriedar Resources, setting the stage for a significant consolidation in the gold exploration sector.

Mt Malcolm Mines NL has suspended trading of its M2MOA securities pending regulatory compliance, signaling a cautious pause for investors.

Imagion Biosystems reports encouraging findings from its Wayne State University collaboration, supporting a lower dose for its MagSense® HER2 imaging agent ahead of a planned FDA IND submission in Q4 2025.

Black Dragon Gold has withdrawn its application to classify the Salave Gold Project as a Project of Strategic Interest in Asturias, Spain, planning a stronger resubmission backed by legal clarity and community support.

Locate Technologies has dispatched its Scheme Booklet to shareholders, outlining the proposed acquisition by Locate NZ and urging a vote in favour at the upcoming virtual meeting.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.